US health authorities have approved the resumption of immunization with the Johnson & Johnson vaccine, which was suspended in the country on April 13 to investigate several cases of thrombosis.
The Center for Disease Control and Prevention (CDC) announced last night that the use of the Johnson & Johnson vaccine should continue in the US, assessing that the benefits outweigh the risks in people aged 18 and over.
The American laboratory decided to take a break in its use while investigating several cases of developing serious blood clots in women after receiving the vaccine.
The US Food and Drug Administration (FDA) and CDC are confident that the vaccine is safe and effective in preventing Covid-19, the two agencies said.
"The data available so far indicate that the risk" of thrombosis is "very low," the two agencies said, adding that they will continue to closely monitor and examine the risk.
The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) said in a joint statement that health systems and the public will be alerted to the risk of a potentially fatal syndrome associated with the formation of blood clots with low platelet counts.
"We are no longer recommending a pause in the use of that vaccine," CDC Director Rochelle Walensky said at a press conference, adding that the Johnson & Johnson vaccine can continue to be used immediately.
Earlier yesterday, the experts of the American health agency recommended to continue vaccination with Johnson's serum.
In the US, 7,98 million doses of the Johnson & Johnson vaccine have already been administered.
According to the data presented yesterday, of the 3,99 million vaccinated women, 15 of them developed serious cases of blood clots and three died.
13 of them were younger than 50 years old, and two were between 50 and 64 years old.
There were no cases of clots in vaccinated men.
Some experts yesterday pointed out the advantages of this vaccine, which is given only in one dose, and can be stored in ordinary refrigerators and be more easily accessible to vulnerable groups, compared to rare cases of thrombosis.
The Johnson & Johnson vaccine is 66 percent effective in preventing moderate to severe cases of covid-19, according to clinical trials conducted on about 40.000 people over the age of 18 in several countries around the world.
Although a link between the vaccine and blood clots has not been demonstrated, scientists believe that this is a "probable cause" of clots, which have also been observed with the AstraZeneca vaccine.
Johnson & Johnson and AstraZeneca use vectored adenovirus technology as do Russia's Sputnik V and China's Cansino.
See more:
Download the app and follow the news
FOLLOW US ON
